Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Topas Therapeutics GmbH

topas-therapeutics.com

Latest From Topas Therapeutics GmbH

Topas To Enter Clinic In 2018

Timm Jessen, CEO of Topas Therapeutics, talks to Scrip's Lucie Ellis about his journey through the pharma and biotech sector and what lies ahead for his current company.

Research and Development Strategies Research & Development

Deals Shaping The Medical Industry, September 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2017.

Deals Medical Device

Topas Bags Big Pharma Partner With Lilly Pact

Eli Lilly is impressed with the privately held German biotech spun out of Evotec which is pursuing a novel liver-based immune tolerance approach.

Deals Immune Disorders

Appointments: Crescendo, Shield, Sarepta, Verona, Hansa, Astellas and Pluristem

This week’s roundup includes various high-level appointments by companies including Vencerx Therapeutics, which has elected a new CEO, Shield Therapeutics, Crescendo Biologics, Pluristem Therapeutics, Sarepta Therapeutics and Verona Pharma.

Appointments BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Inflammation
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Topas Therapeutics GmbH
  • Senior Management
  • Timm Jessen, PhD, CEO
    Johannes Pohlner, COO
    Rupert Sandbrink, MD, PhD, Chief Dev. Officer & CMO
  • Contact Info
  • Topas Therapeutics GmbH
    Phone: 40 47196 320
    Falkenried 88, Haus A
    Hamburg, 20251
    Germany
Advertisement
Advertisement
UsernamePublicRestriction

Register